Amarantus Bioscience Holdings Inc (AMBS)

[MagicCap]

"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus." said Henri Huttunen, Ph.D., CSO and Partner from Hermo Pharma Oy Ltd., a privately owned, venture capital backed company based in Finland working on therapeutic approaches for currently untreatable medical needs, particularly Parkinson's disease.

"As Henri mentioned, they challenged the patents because they believed that they covered too many possible variants of the protein and it therefore "causes "an undue burden" to anyone who would like to test these variants for activity". The only way I can interpret this is that anyone looking to test different variants of MANF will be forced to go through AMBS as it has patents "that cover all sequences with 90% homology to MANF"."

Just curious what your take is on this.

I like how you're trying spread fear so you can buy lower. Good luck with that.